PharmAust (ASX:PAA) CEO to depart; interim CEO named

PharmAust announced the resignation of CEO Michael Thurn due to personal reasons, with a four-month notice period per his contract.

Thurn's tenure saw significant advancements, including leading the Phase 1 MEND Study of monepantel for motor neurone disease, progressing to Phase 2/3 studies, investor engagement, and capital raisings.

The company appointed John Clark, the current COO, as interim CEO.